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ABSTRACT
Colorectal cancer is a major cause of cancer death and approximately 20% arises within serrated polyps,
which are under-recognized and poorly understood. Human serrated colorectal polyps frequently exhibit
both oncogenic BRAF mutation and widespread DNA methylation changes, which are important in
silencing genes restraining neoplastic progression. Here, we investigated whether in vivo induction of
mutant Braf is sufﬁcient to result in coordinated promoter methylation changes for multiple cancer-
related genes. The BrafV637E mutation was induced in murine intestine on an FVB;C57BL/6J background
and assessed for morphological and DNA methylation changes at multiple time points from 10 days to 14
months. Extensive intestinal hyperplasia developed by 10 days post-induction of the mutation. By 8
months, most mice had murine serrated adenomas with dysplasia and invasive cancer developed in 40%
of mice by 14 months. From 5 months onwards, Braf mutant mice showed extensive, gene-speciﬁc
increases in DNA methylation even in hyperplastic mucosa without lesions. This demonstrates that
persistent oncogenic Braf signaling is sufﬁcient to induce widespread DNA methylation changes. This
occurs over an extended period of time, mimicking the long latency followed by rapid progression of
human serrated neoplasia. This study establishes for the ﬁrst time that DNA methylation arises slowly in
direct response to prolonged oncogenic Braf signaling in serrated polyps; this ﬁnding has implications








The serrated colorectal neoplasia pathway describes the pro-
gression of morphologically serrated polyps to cancer. The
malignant potential of serrated polyps has only been under-
stood in the last decade and this pathway is now accepted to
account for approximately 20% of all colorectal cancers. Muta-
tion of the BRAF oncogene has been exclusively associated with
serrated polyp morphology [1]. BRAF mutant polyps and can-
cers commonly methylate a deﬁned subgroup of CpG islands, a
phenomenon termed the CpG Island Methylator Phenotype
(CIMP) [2–5]. CIMP-speciﬁc methylation facilitates malignant
progression of serrated polyps by targeting tumor suppressor
genes involved in escape from oncogene induced senescence
(e.g., CDKN2A), inappropriate activation of Wnt signaling
(e.g., SFRP1,2,5), and mismatch repair deﬁciency (e.g., MLH1)
[6]. The cause of CIMP in colorectal cancer has been unknown.
It is important to understand the mechanism by which CIMP
develops, as this will impact chemoprevention and therapeutic
strategies for this molecularly distinct subgroup of polyps and
cancers.
Studies to date have been inconclusive regarding the timing
of BRAF mutation and altered DNA methylation in colorectal
cancer. Clinically, BRAF mutation occurs in the earliest identi-
ﬁable serrated lesions, including aberrant crypt foci [7], micro-
vesicular hyperplastic polyps, and the vast majority of sessile
serrated adenomas [8]. Altered DNA methylation has been
observed in histologically normal colorectal mucosa of patients
with serrated polyps [9]; however, CIMP marker panel methyl-
ation is not detected in normal mucosa but is common in ses-
sile serrated adenomas and BRAF mutant cancers [4,5,10]. In
vitro knockdown of BRAF produced genome-wide alterations
in DNA methylation proﬁles in two BRAF mutant thyroid [11]
and three BRAF mutant melanoma cell lines [11,12]. Introduc-
tion of the BRAFV600E mutation to a CIMP colonic cell line was
reported to induce methylation of the MLH1 gene promoter
[13]; however, another report of stable expression of the
BRAFV600E mutation in a CIMP-negative cell line for up to 27
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passages failed to show increased methylation that differed
from control cells [14]. A recent study of BRAF mutant human
organoids did not demonstrate development of CIMP; how-
ever, it is unclear how long the organoids were cultured [15].
By inducing the murine equivalent of the human BRAFV600E
mutation speciﬁcally in the intestine of adult mice, we have, for
the ﬁrst time, studied in detail, at multiple time points, DNA
methylation alterations accompanying initiation and progres-
sion of serrated neoplasia in vivo. We demonstrate that induc-
tion of the BRAF mutation in normal intestinal cells results in
the accumulation of DNA methylation defects slowly over
time, mimicking progression of the serrated neoplasia pathway
in humans.
Results
Morphological progression of murine serrated neoplasia
Intestine-speciﬁc induction of the Braf mutation at 2 weeks of
age resulted in MAPK pathway activation (Supplementary
Figure 1) and extensive hyperplasia in all mice within 10 days
(Figure 1A–D, Table 1), which persisted lifelong. In the colon,
the hyperplasia resembled a human microvesicular hyperplastic
polyp (Figure 1B). No discrete serrated lesions developed in the
colon of any mice. Murine serrated hyperplasia (mSH) of the
small intestine varied by region. In the duodenum, the hyper-
plasia was exuberant and as the mice aged the villi displayed
cellular crowding, pseudostratiﬁcation, and occasional mitotic
activity, enlarged nuclei, and a vesicular chromatin pattern.
These changes gradually reduced in severity distally and were
inconspicuous by the early jejunum where the villi, although
still hyperplastic, displayed a more uniform cytology.
The earliest identiﬁable discrete lesions were seen in 50% of
mice 10 weeks post-induction of the Braf mutation, consisting
of dilatation and mucinous differentiation of some crypt bases
(Figure 1E). These increased in number and extent with age
and were histologically reminiscent of human sessile serrated
adenomas. We refer to these lesions as murine serrated
precursors (mSP). These rarely involved more than 2–4 crypts.
As the mice aged, some precursor lesions displayed a more
eosinophilic cellular appearance towards the luminal aspect,
developing dysplasia and forming large, macroscopically identi-
ﬁable tumors (Figure 1F). We refer to these lesions as murine
serrated adenoma (mSA), as opposed to the mSA with high-
grade dysplasia designation used by Rad et al. [16] These were
occasionally present at early time points (1/6 mice at 10 weeks,
1/12 mice at 5 months), but were present in the majority of
mice at 8 months (8/10), 10 months (14/18), and 14 months
(8/8) (Table 1). An invasive cancer was identiﬁed in a mouse
8 months post-induction of the Braf mutation as well as 3/8
mice at 14 months, one of which had metastasized to the liver
(Figure 1G, Table 1). The average number and size of lesions
per mouse increased during the study period, with an average
of 11.9 lesions per mouse at 14 months, averaging 12.7 mm in
diameter (Table 1).
Small lesions reminiscent of human conventional tubular
adenomas were also observed in 6 Braf mutant mice but no
control mice. We have designated these as murine tubular ade-
nomas (mTA). These were present in the proximal colon in
4 mice (2 at 10 months, 2 at 14 months), and the jejunum of a
5-month and a 10-month-old mouse.
BRAF mutation induces widespread, gene-speciﬁc DNA
hypermethylation in vivo
Mucosa from the proximal small intestine was sampled in
BrafV637E and age-matched control BrafCA littermates at
10 days, 10 weeks, 5 months, 8 months, 10 months, and 14
months after injection of tamoxifen or vehicle, respectively. As
the mice aged, there was a dramatic and gene-speciﬁc increase
in DNA methylation in Braf mutant compared to Braf wild
type intestinal mucosa (Figure 2a). Regression lines were ﬁt to
the data for the control Braf wild type and the hyperplastic
Braf mutant tissue groups versus time (Figure 2b). The slope
for the Braf wild type samples was signiﬁcantly greater than
0 (P = 0.0008), demonstrating age-related increases in DNA
Figure 1. Morphological changes following intestinal Braf mutation. (A) Braf wild type colon and (B) Braf mutant colon 10 days after induction of the mutation. (C) Braf
wild type small intestine and (D) Braf mutant small intestine 10 days after induction of the mutation. (E) A murine serrated precursor at 5 months. (F) A murine serrated
adenoma with an overtly dysplastic zone at 14 months. (G) A moderately differentiated invasive cancer arising from a murine serrated adenoma at 14 months post-induc-
tion and (H) the same cancer showing retention of MLH1 protein.
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methylation for a subset of genes (Supplementary Table 1). The
accumulation of methylation changes in these and additional
genes was accelerated by induction of the Braf mutation
(Table 2). The difference in the slopes between the Braf wild
type and mutant mucosal samples was highly signiﬁcant
(P<0.0001), reﬂecting the temporal accumulation of DNA
methylation events following induction of the Braf mutation.
To conﬁrm that the increase in methylation observed in hyper-
plastic mucosa was not a result of unidentiﬁed microscopic
lesions, we also assessed the samples from the jejunum 10 cm
distal to the gastro-duodenal junction and from the proximal
colon, two locations where hyperplasia was present but no
discrete lesions were observed. A similarly dramatic increase in
DNA methylation was observed at both these sites in Braf
mutant samples compared to Braf wild type samples
(Figure 2C).
There were three major patterns of methylation observed for
the genes examined: Type A, in which methylation accumu-
lated with age but was accelerated by mutant Braf (Figure 3A);
Type B, in which hypermethylation was limited to Braf mutant
samples (Figure 3B); and Type C, where methylation was
largely limited to murine serrated adenomas and cancers
(Figure 3C). This model may be investigated to identify epige-
netic events associated with progression of serrated neoplasia.
Figure 2. Temporal and gene-speciﬁc accumulation of DNA hypermethylation following Braf mutation. (A) Heat map showing hypermethylated genes in yellow, com-
pared to unmethylated genes in blue. There was a dramatic age-related and gene-speciﬁc increase in DNA methylation in Brafmutant proximal small intestine and lesions
compared to Braf wild type mucosa. (B) The average percentage methylation is plotted across time-points for Braf wild type proximal small intestine (blue), Braf mutant
small intestine (yellow) and lesions (red). (C) At 12 months the proximal jejunum and colon were signiﬁcantly methylated in Braf mutant (yellow) compared to Braf wild
type (blue) mucosa. P<0.0001.
Table 1. Temporal accumulation of serrated morphology.
Time Post Induction












Average Size of Largest
Lesion per Mouse (mm) 
10 days 6 100 0 0 0 0 0 0
10 weeks 6 100 3/6 (50) 1/6 (17) 0 0 0.8 0.2
5 months 12 100 9/12 (75) 1/12 (8) 0 0 4.1 0.2
8 months 10 100 6/10 (60) 8/10 (80) 1/10 (10) 0 5.0 4.3
10 months 18 100 17/18 (94) 14/18 (78) 0 0 11.4 4.8
14 months 8 100 6/8 (75) 8/8 (100) 3/8 (38) 1/8 (13) 11.9 12.7
 ’Lesion’ encompasses all mSP, mSA and cancers
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Genes differentially methylated between Braf mutant hyper-
plastic mucosa and murine serrated adenomas and/or cancers
are shown in Supplementary Table 2. Signiﬁcantly hypermethy-
lated genes that may have a role in progression of serrated neo-
plasia include Sfrp5 (P = 9.3 £ 10¡9), Hs3st2 (P = 2.1 £ 10¡5),
and Cxcl12 (P = 5.0 £ 10¡4). The most striking examples were
Sfrp5, which had a methylation level of >50% in 18/21 (86%)
lesions compared to <0.5% methylation in 18/18 control sam-
ples and 59/60 Braf mutant hyperplastic mucosa samples. Simi-
larly, Hs3st2 had a methylation level >50% in 14/21 (66.7%)
lesions compared to a single Braf mutant, hyperplastic sample,
and no control samples.
Bhlhb9 was the only gene to exhibit gender-speciﬁc methyla-
tion. This appeared to be imprinted, with control female
murine mucosa averaging 48.7% methylation across all time
points, compared to 0.2% for male animals (P<0.0001). In Braf
mutant hyperplasia samples, Bhlhb9 methylation signiﬁcantly
increased over time from 5 months in both males and females.
In males Bhlhb9 methylation averaged 4.6% at 5 months com-
pared to 63–73% at 8 months (Supplementary Figure 2).
Murine colonic organoids were cultured for 4 weeks post-
induction of the Braf mutation in vitro. Complete conversion
to the Braf mutant allele was observed (Supplementary Figure
3); however, at this time point there was not signiﬁcant increase
in DNA methylation in any of the 94 genes examined.
Mismatch repair status of Braf mutant mSA and cancers
Microsatellite instability status was examined in the 5 mSA and
3 cancers sampled at 14 months, supplemented with an addi-
tional 3 mSA and 4 cancers from 7 additional mice at 14
months. Of these 15 samples, none met the criteria for micro-
satellite instability based on the seven microsatellite markers
examined. Two cancers and two mSA had a 20–30 bp deletion
in the mBat67 marker; however, all other markers were stable.
These lesions all retained immunohistochemical expression of
MLH1 (Figure 1H). Based on the PCR methylation array data,
no sample was methylated forMlh1.
Discussion
A signiﬁcant subset of colorectal cancers are characterized by
oncogenic BRAF mutation and widespread, coordinate DNA
hypermethylation. The unique origin of these cancers in ser-
rated polyps has been described over the last decade. However,
the temporal relationship between BRAF mutation and altered
DNA methylation in early serrated tumorigenesis is not well
understood. Here, we present an in vivomodel that morpholog-
ically mimics human serrated neoplasia and that slowly accu-
mulates DNA methylation changes over many months,
congruent with the slow development of serrated adenomas
which then transition to high grade dysplasia and ultimately
cancer (Figure 4).
Intestine-speciﬁc induction of the Braf mutation in adult
mice rapidly induced prolonged hyperplasia throughout
the small and large intestine, consistent with the constitutive
Villin-Cre model reported by Rad et al. [16]. In contrast to the
mSA with low-grade dysplasia described by Rad et al., we
deﬁned subtle areas of crypt dilatation and mucinous differenti-
ation as murine serrated precursors (mSP). These were diminu-
tive and were reminiscent of small human sessile serrated
adenomas. By 8 months the majority of animals had developed
murine serrated adenomas (mSA) that are likely comparable to
the mSA with high-grade dysplasia described by Rad et al. By
14 months, mice developed invasive cancer. Thus, the present
study, incorporating careful examination of the morphology by
a gastrointestinal pathologist, conﬁrms that induction of an
oncogenic Braf mutation in murine intestine is sufﬁcient to
create a mouse model that closely mimics human serrated
neoplasia.
The present study is the ﬁrst to demonstrate the accumula-
tion over time of multiple gene-speciﬁc DNA methylation
events, seemingly driven by prolonged oncogenic Braf signaling
in this rapidly proliferating tissue. This methylation was appar-
ent even in tissue where the only morphological change was
stable hyperplasia and thus is unlikely to be secondary to other
genetic changes associated with the progression of malignancy.
Consistent with a previous study, methylation was not observed
in Braf mutant organoids cultured for 1 month, highlighting
Table 2. Temporal methylation changes in Braf mutant mice.
Gene Methylation Ratio P-value Adjusted P-Value
Dkk2 384.2 1.8E-26 1.7E-24
Tmeff2 255.0 1.1E-22 5.0E-21
Rprm 245.1 2.7E-22 8.3E-21
Cdh13 232.0 9.4E-22 2.2E-20
Pcdh10 224.5 2.0E-21 3.8E-20
Prom1 211.3 7.9E-21 1.2E-19
Nid1 206.7 1.3E-20 1.5E-19
Reck 207.3 1.2E-20 1.5E-19
Igfbp7 203.0 1.9E-20 2.0E-19
Apba2 183.8 1.8E-19 1.7E-18
Slit3 177.4 3.8E-19 3.3E-18
Wt1 175.1 5.0E-19 3.9E-18
Sst 162.7 2.4E-18 1.8E-17
Lrrc3b 125.6 4.9E-16 3.3E-15
Crabp1 122.9 7.5E-16 4.3E-15
Gdnf 123.1 7.3E-16 4.3E-15
Prdm5 122.7 7.8E-16 4.3E-15
Cdh4 115.5 2.5E-15 1.3E-14
Grin2a 89.2 2.9E-13 1.4E-12
Ptgis 67.8 3.2E-11 1.5E-10
Sfrp2 65.6 4.7E-11 2.1E-10
Bhlhb9 63.8 7.3E-11 3.1E-10
Igf2 54.3 7.7E-10 3.0E-09
Tcfap2c 54.3 7.8E-10 3.0E-09
Dkk3 47.8 4.4E-09 1.7E-08
Rassf1 45.1 9.4E-09 3.4E-08
Id4 41.7 2.5E-08 8.8E-08
Uchl1 33.0 3.8E-07 1.3E-06
Bmp3 19.7 4.2E-05 1.4E-04
Epb4-1l3 19.6 4.3E-05 1.4E-04
Wnt5a 14.9 2.9E-04 8.8E-04
Pax2 14.6 3.3E-04 9.5E-04
Sfrp1 14.6 3.3E-04 9.5E-04
Adamts1 13.2 6.1E-04 0.002
Cdkn2a 12.8 7.2E-04 0.002
Cxcl12 12.8 7.3E-04 0.002
Sfrp4 12.4 8.5E-04 0.002
Dact2 10.6 0.002 0.005
Igfbp3 10.4 0.002 0.005
Msx1 10.1 0.002 0.006
Cnr1 9.8 0.003 0.006
Ccna1 9.0 0.004 0.009
Mal 9.1 0.004 0.009
Ephb2 7.6 0.008 0.017
Galr2 7.3 0.009 0.019
P-value corrected for false discovery rate (Benjamini-Hochberg).
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Figure 3. Patterns of DNA methylation accumulation included (A) Type A methylation that accumulated with age but was accelerated by mutation of Braf, (B) Type B
methylation changes speciﬁc to Braf mutant tissue and (C) Type C methylation changes speciﬁc to murine serrated adenomas and/or cancers.
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the additive value of long term in vivo models [15]. Despite
using a murine-speciﬁc PCR array that included 94 genes previ-
ously reported to be methylated in human colorectal cancer, the
DNA methylation that occurred following Braf mutation was
limited to a deﬁned subset of these gene promoters, consistent
with the speciﬁc nature of human CIMP [2,5]. By 5 months,
there was a highly signiﬁcant, global increase in DNA methyla-
tion in Braf mutant epithelium compared to age-matched con-
trol samples. Signiﬁcant and persistent increases were seen in
several genes, including Igfbp7, which is a human CIMP target
gene that, when silenced, may facilitate escape from oncogene
induced senescence [14]. By 8 months, signiﬁcant methylation
had been accumulated, including in Crabp1, which is highly
speciﬁc for human CIMP [5,17]. Maximum global methylation
changes were reached by 10 months, including speciﬁc hyper-
methylation of the Wnt pathway gene Sfrp2.
Differential methylation of a number of genes was signiﬁ-
cantly associated with development of mSA or cancer, includ-
ing the Wnt pathway genes Wnt5a [18] and Sfrp5 [19]. Two
studies have reported methylation of deﬁned sites within the
p16INK4a gene promoter in murine mSA or cancer induced by
intestinal Braf mutation [16,20]. At the CpG sites assayed in
the present study, p16INK4a was not signiﬁcantly methylated at
any time point assessed for any sample. This may reﬂect strain-
speciﬁc sequence differences mediating p16 promoter hyperme-
thylation, or may be due to the different CpG sites assessed in
these studies. The study by Rad et al. showed an increase in
average p16INK4a transcript expression with progression to
high-grade dysplasia. The average p16INK4a expression level
remained elevated in cancers, but was reduced somewhat, likely
reﬂecting silencing due to acquired promoter hypermethylation
and silencing in only a proportion of mSAs and cancers. This is
consistent with what has been observed during progression of
human serrated neoplasia [4].
A surprising ﬁnding was that in contrast to the model pre-
sented by Rad et al., we did not observe microsatellite instability
in the current study, despite using the same marker panel [16].
Our ﬁndings were consistent with a lack of MLH1 methylation
and retained MLH1 protein expression in all samples exam-
ined. Rad et al. showed MSI in 9/23 mSA with high-grade dys-
plasia and 3/8 cancers, but did not present data for MLH1
methylation or protein expression. We expanded our study
numbers to investigate a total of 8 mSA and 7 invasive cancers
from 14-month-old mice but still did not observe microsatellite
instability or MLH1 protein loss in any of these lesions. In
humans, single nucleotide polymorphisms have been associated
with increased risk of site-speciﬁc DNA methylation,
particularly for the -93 SNP in the MLH1 promoter [21]. It is
possible that strain differences between the current (FVB/BL6)
and Rad et al. models may have impacted such a site in mice.
These mice may therefore present an excellent model to study
the development BRAF mutant, microsatellite stable cancer in
vivo, which is a subgroup of human colorectal cancers with a
particularly poor prognosis [22].
The speciﬁcity of gene methylation occurring in stable
hyperplasia at deﬁned time points is intriguing and may relate
to a sequence-speciﬁc threshold of MAPK signaling required to
trigger DNA methylation. This is consistent with the model
proposed by Fang et al., in which MAPK signal transduction
increases phosphorylation of MAFG and sequence-speciﬁc pro-
moter binding and hypermethylation by DNMT3b [23]. It is
possible that prolonged exposure to elevated MAPK signaling
is required for efﬁcient phosphorylation of MAFG (or other)
transcription factors involved in this process. Promoters with
multiple binding sites for relevant transcription factors may be
more susceptible to DNA hypermethylation by this mecha-
nism. We did not observe an over-representation of MAFG
consensus binding sites in silico for genes signiﬁcantly hyper-
methylated in this model. Consistent with this was the lack of
promoter methylation for MLH1 in any samples in this study,
despite being the classic example of MAFG-mediated methyla-
tion presented by Fang. This may be due to different MLH1
CpG sites being assessed in the present study; however, the lack
of MLH1 methylation was consistent with the retention of mis-
match repair efﬁciency indicated by microsatellite stability and
retention of the MLH1 protein. An alternate hypothesis is that
methylation of MLH1 may be mediated by DNA sequences
that vary between humans and mice, or even different strains
of mice.
Despite the high rate of conversion to the mutant Braf allele
and development of stable hyperplasia throughout the intestine,
the neoplastic phenotype was predominantly localized to the
duodenum and proximal jejunum. This is a common feature of
murine models of colorectal carcinogenesis and is also observed
in models of conventional adenomas driven by Apc mutation.
Despite this morphological gradient, there was not a concomi-
tant DNA methylation gradient, based on the 94 genes assessed
in this study.
This study substantially advances our understanding of the
role of BRAFmutation in orchestrating multiple DNA methyla-
tion changes that underlie progression of serrated neoplasia.
We have presented a conditional murine model that faithfully
recapitulates human serrated polyp development, both mor-
phologically and in terms of accumulation of gene-speciﬁc
Figure 4. Model of murine serrated neoplasia initiated by intestinal Braf mutation. At 10 days post-induction of the Braf mutation, unstable hyperplasia is evident in the
proximal small intestine. Murine serrated polyps (mSP) develop by 10 weeks and by 5 months murine serrated adenomas (mSA) are seen. mSP, mSA and cancer can be
seen by 8–14 months. This is accompanied by the accumulation of gene-speciﬁc DNA methylation changes over time.
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DNA methylation changes. For the ﬁrst time, we have demon-
strated in vivo that Braf mutation is sufﬁcient to induce a
methylator phenotype and that this is associated with a pro-
tracted time frame, consistent with the long dwell time
observed for human serrated neoplasia. This model will provide
a valuable tool for development of chemoprevention and thera-
peutic strategies for BRAF mutant colorectal neoplasia, as well
as to further probe the mechanism by which CIMP is
established.
Materials and methods
BRAF mutant murine model
Mice homozygous for the conditionally active BrafV637E mutant
allele (BrafCA/CA, FVB background) (analogous to the human
BRAFV600E mutation) [24] were crossed with heterozygous Vil-
lin-CreERT2/wt mice (C57BL/6J background) [25] and genotyped
at 10–12 days old (Supplementary Methods). Induction of the
Braf mutation was directed to the intestine at 2 weeks of age
using a single 75 mg/kg intraperitoneal injection of tamoxifen
(Sigma-Aldrich). Control mice had the same genotype but were
injected with vehicle only. At deﬁned time points the gastroin-
testinal tract from esophagus to rectum was opened longitudi-
nally and mucosal scrapings were sampled from the proximal
small intestine, the jejunum 10 cm distal to the gastroduodenal
junction and the proximal colon. Macroscopic lesions were
bisected for molecular and histological assessment. The entire
remaining intestine was examined histologically. Animal breed-
ing and experimental protocols were approved by the QIMR
Berghofer Animal Ethics Committee (P1208).
Morphological assessment of murine intestinal epithelium
Hematoxylin and eosin stained sections were examined by an
anatomical pathologist (CL). BrafV637E samples were compared
with age-matched Braf wild type littermates. Histological type
and number of lesions were recorded for all mice. Lesions were
characterized predominantly using the terminology of Rad et
al. [16] as murine serrated adenomas with either low grade or
high grade dysplasia (mSA-LGD or mSA-HGD), dependent on
the degree of architectural and cytological abnormality. As
murine small bowel contains very little muscularis mucosae
and submucosa, it was difﬁcult to distinguish between intramu-
cosal carcinoma and submucosal invasive carcinoma. We
therefore designated invasive carcinoma only in unequivocal
cases that invaded the muscularis propria or beyond. Closely
located lesions were counted separately if at least one layer of
normal epithelial cells was seen between the lesions.
DNA methylation proﬁling in murine tissue
Proximal small intestinal epithelium was assessed for DNA
methylation changes at 10 days, 10 weeks, 5 months, 8 months,
10 months and 14 months post-induction of the Braf mutation
(minimum 5 samples per time point) with age-matched Braf
wild type littermates (n = 3 for each time point). Mucosal
scrapings were snap frozen in liquid nitrogen and genomic
DNA was extracted using AllPrep Kits (Qiagen). DNA
methylation was assessed from a total of 2 mg DNA using Epi-
tect Methyl II Complete PCR Arrays (Qiagen) that include 94
genes that have previously been found to be methylated in colo-
rectal cancer. Following digestion with either a methylation-
sensitive or methylation-dependent restriction enzyme, DNA
was ampliﬁed using a BioRad CFX384 real-time cycler and the
percentage of gene methylation was calculated using the Epitect
data analysis template. Heatmaps were generated using hierar-
chical clustering with a Pearson correlation measurement for
similarity.
Murine colonic organoid culture
Organoids were cultured from heterozygous BrafCA/wt / Villin-
CreERT2/wt colonic epithelial cells [26] and plated in a two-layer
matrigel format [27]. Established organoids were treated with
vehicle or 1 mM 4-dyroxytamoxifen to generate BRAFV637E/wt
mutant organoids. PCR genotyping conﬁrmed efﬁcient recom-
bination of the ﬂoxed allele (Supplementary Figure 2). Braf
mutant organoids were passaged every 5–7 days and harvested
at day 30 for genomic DNA isolation using a Qiagen AllPrep
Kit columns.
Mismatch repair status
Immunostaining for the MLH1 mismatch repair protein was
performed using the BD Pharmingen G168-15 MLH1 primary
antibody at a 1/100 dilution for 60 minutes at room tempera-
ture. Antigen retrieval was at pH 9.0 using Target Retrieval
Solution (Agilent Technologies). Background Sniper (Biocare
Medical) and 5% peroxidase blocks were applied for 30 minutes
each to minimize background staining in the murine tissue.
Microsatellite instability was assessed as a functional readout of
mismatch repair activity using a panel of 7 murine microsatel-
lite markers (mBat26, mBat37, mBat67, TG27, GA29, A33, and
A27) [16]. PCR products were separated on an ABI PRISM
3100 Genetic Analyzer to assess altered fragment size in tumors
compared to matched intestinal tissue for each sample. Methyl-
ation status of the MLH1 mismatch repair gene promoter was
extracted from the Epitect Methyl II PCR Array.
Statistical analysis
Continuous variables were analysed using Student’s T-test. Lin-
ear regressions were used to analyze continuous variables ver-
sus time. Parallelism of regression lines models was assessed
using multiple regression, which included slope by group inter-
action terms. The family wise error rates for comparisons of
large sets of genes were controlled using the Benjamini-Hoch-
berg procedure for adjusting P values to control the false dis-




DNA for genotyping was extracted from the tail tissue using
QuickExtract (EpiBio). The Villin-Cre-ERT2 allele was genotyped
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by qPCR (2.5 mM MgCl2, 0.25 mM dNTP, 0.5 mM forward
primer (5’-CAA GCC TGG CTC GAC GGC C-3’), 0.5 mM
reverse primer (5’-CGC GAA CAT CTT CAG GTT CT-3’),
0.5 mM forward bthal positive control primer (5’-TGA GAA
GGC TGC TGT CTC TTG-3’) and reverse bthal positive control
primer (5’-CAG AGG ATA GGT CTC CAA AGC TA-3’), 0.25
uM SYTO9, 4 uL 5X GoBuffer (Promega), 0.5 U GoTaq (Prom-
ega) under the following thermal cycling conditions: 94⁰C for 120
s; 40 cycles of: 94⁰C for 30 s, 55⁰C for 30 s, 72⁰C for 45 s followed
by 72⁰C for 300 s, 50⁰C for 120 s and high resolution melt from
80⁰C to 92⁰C ramping by 0.2⁰C/step) and subsequent high reso-
lution melt proﬁle analysis. BRAFCA was similarly genotyped via
qPCR (2.5 mM MgCl2, 0.25 mM dNTP, 0.5 mM forward primer,
0.5 mM reverse primer, 4 uL 5X GoBuffer, 0.5 U GoTaq under
the following thermal cycling conditions: 94⁰C for 120 s; 40 cycles
of: 94⁰C for 30 s, 58⁰C for 30 s, 72⁰C for 40 s followed by 72⁰C
for 300 s, 50⁰C for 120 s and high resolution melt from 72⁰C to
92 ramping by 0.2⁰C/step) and subsequent high resolution melt
proﬁle analysis.
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